Shelton Capital Management Acquires 105,101 Shares of Bristol-Myers Squibb (NYSE:BMY)

Shelton Capital Management boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 95.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 215,184 shares of the biopharmaceutical company's stock after buying an additional 105,101 shares during the quarter. Shelton Capital Management's holdings in Bristol-Myers Squibb were worth $12,171,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BMY. United Bank grew its position in Bristol-Myers Squibb by 2.7% during the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 456 shares in the last quarter. Morse Asset Management Inc grew its holdings in shares of Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after buying an additional 2,000 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in Bristol-Myers Squibb by 25.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 49,252 shares of the biopharmaceutical company's stock worth $2,548,000 after acquiring an additional 9,836 shares in the last quarter. Dunhill Financial LLC boosted its position in Bristol-Myers Squibb by 39.8% during the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 189 shares during the period. Finally, MML Investors Services LLC grew its stake in Bristol-Myers Squibb by 1.5% during the 3rd quarter. MML Investors Services LLC now owns 313,688 shares of the biopharmaceutical company's stock valued at $16,230,000 after acquiring an additional 4,554 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BMY shares. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price objective for the company from $63.00 to $70.00 in a research report on Monday, December 16th. Citigroup upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Finally, Truist Financial lifted their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $57.67.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the firm's stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded up $0.22 during midday trading on Friday, reaching $50.68. 13,408,290 shares of the company's stock were exchanged, compared to its average volume of 12,926,949. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company's 50 day simple moving average is $57.71 and its two-hundred day simple moving average is $56.78. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The firm has a market capitalization of $103.11 billion, a PE ratio of -11.46, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.89%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.